Form 8-K - Current report:
SEC Accession No. 0001193125-25-230118
Filing Date
2025-10-03
Accepted
2025-10-03 16:06:43
Documents
12
Period of Report
2025-09-23
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d63317d8k.htm   iXBRL 8-K 26746
  Complete submission text file 0001193125-25-230118.txt   137838

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20250923.xsd EX-101.SCH 2867
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20250923_lab.xml EX-101.LAB 17234
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20250923_pre.xml EX-101.PRE 10823
14 EXTRACTED XBRL INSTANCE DOCUMENT d63317d8k_htm.xml XML 3507
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 251373792
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)